唑烷酮类药物对非结核分枝杆菌的活性，包括大环内酯类耐药的临床分离株。
Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
出版信息
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0230620. doi: 10.1128/AAC.02306-20.
Abstract
We evaluated the activities of oxazolidinone antibiotics, including linezolid, sutezolid, and delpazolid, against clinical nontuberculous mycobacteria (NTM) isolates. Regardless of macrolide resistance, for Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium kansasii, sutezolid showed the lowest MIC and minimal bactericidal concentration (MBC) values among oxazolidinone antibiotics. However, for Mycobacterium abscessus and Mycobacterium massiliense, the MIC and MBC for all oxazolidinone antibiotics showed similar values. Oxazolidinone antibiotics warrant further investigation as potential treatment for NTM.
摘要
我们评估了包括利奈唑胺、舒托必利和德尔帕佐利德在内的恶唑烷酮类抗生素对临床非结核分枝杆菌（NTM）分离株的活性。无论大环内酯类药物是否耐药，对于鸟分枝杆菌、胞内分枝杆菌和堪萨斯分枝杆菌，舒托必利在恶唑烷酮类抗生素中表现出最低的 MIC 和最小杀菌浓度（MBC）值。然而，对于脓肿分枝杆菌和马萨诸塞分枝杆菌，所有恶唑烷酮类抗生素的 MIC 和 MBC 值都显示出相似的值。恶唑烷酮类抗生素作为 NTM 的潜在治疗方法值得进一步研究。
相似文献
1
Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.唑烷酮类药物对非结核分枝杆菌的活性，包括大环内酯类耐药的临床分离株。
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0230620. doi: 10.1128/AAC.02306-20.
2
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌（包括大环内酯类耐药临床分离株）的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
3
Evaluation of the Efficacy of Novel Oxazolidinone Analogues against Nontuberculous Mycobacteria In Vitro.新型恶唑烷酮类似物对非结核分枝杆菌体外抗菌活性的评价
Jpn J Infect Dis. 2015;68(6):520-2. doi: 10.7883/yoken.JJID.2014.498. Epub 2015 May 12.
4
activity of fidaxomicin against nontuberculosis mycobacteria.对非结核分枝杆菌的 fidaxomicin 活性。
J Med Microbiol. 2022 Jun;71(6). doi: 10.1099/jmm.0.001549.
5
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.迈向非结核分枝杆菌临床折点 - 使用肉汤微量稀释法测定鸟分枝杆菌复合群和脓肿分枝杆菌的流行病学切点值。
Clin Microbiol Infect. 2023 Jun;29(6):758-764. doi: 10.1016/j.cmi.2023.02.007. Epub 2023 Feb 20.
6
Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance.苯并咪唑（SPR719）对有和无克拉霉素或阿米卡星耐药的非结核分枝杆菌临床分离株的活性。
Ann Lab Med. 2024 Jan 1;44(1):92-96. doi: 10.3343/alm.2024.44.1.92. Epub 2023 Sep 4.
7
Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China.氯法齐明对中国北京分离的非结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00072-18. Print 2018 Jul.
8
Activity of Bedaquiline against Nontuberculous Mycobacteria in China.中国贝达喹啉对非结核分枝杆菌的活性
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02627-16. Print 2017 May.
9
Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.依拉环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068922. doi: 10.1128/aac.00689-22. Epub 2022 Aug 9.
10
In vitro activity of tedizolid against the Mycobacterium abscessus complex.替加环素对脓肿分枝杆菌复合群的体外活性。
Diagn Microbiol Infect Dis. 2018 Mar;90(3):186-189. doi: 10.1016/j.diagmicrobio.2017.11.001. Epub 2017 Nov 10.
引用本文的文献
1
The antimicrobial activity of linezolid against unconventional pathogens.利奈唑胺对非传统病原体的抗菌活性。
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
2
Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.唑烷酮类药物对鸟分枝杆菌复合体感染的细胞内和体内活性。
Sci Rep. 2023 Nov 23;13(1):20631. doi: 10.1038/s41598-023-48001-y.
3
Antibiotics in the clinical pipeline as of December 2022.截至 2022 年 12 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
4
Epidemiology of Nontuberculous Mycobacteria in Nanjing and Mutations Associated with Clofazimine Resistance in .南京非结核分枝杆菌的流行病学及与氯法齐明耐药相关的突变
Infect Drug Resist. 2023 May 6;16:2751-2764. doi: 10.2147/IDR.S408986. eCollection 2023.
本文引用的文献
1
Treatment of Mycobacterium abscessus Complex.脓肿分枝杆菌复合体的治疗。
Semin Respir Crit Care Med. 2018 Jun;39(3):362-376. doi: 10.1055/s-0038-1651494. Epub 2018 Aug 2.
2
Treatment of Mycobacterium avium Complex (MAC).鸟分枝杆菌复合体（MAC）的治疗。
Semin Respir Crit Care Med. 2018 Jun;39(3):351-361. doi: 10.1055/s-0038-1660472. Epub 2018 Aug 2.
3
Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic.食物对新型恶唑烷酮类抗生素LCB01-0371单次口服剂量药代动力学特征的影响
Drug Des Devel Ther. 2018 Jun 11;12:1707-1714. doi: 10.2147/DDDT.S155657. eCollection 2018.
4
NTM drug discovery: status, gaps and the way forward.NTM 药物发现：现状、差距和未来发展方向。
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
5
Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review.针对鸟分枝杆菌复合体肺病的干预措施的微生物学结果：系统评价。
Chest. 2018 Apr;153(4):888-921. doi: 10.1016/j.chest.2018.01.024. Epub 2018 Feb 2.
6
Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects.新型恶唑烷酮类抗生素 LCB01-0371 在健康男性受试者中进行 21 天多次口服给药的安全性、耐受性和药代动力学。
J Antimicrob Chemother. 2018 Jan 1;73(1):183-190. doi: 10.1093/jac/dkx367.
7
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).英国胸科学会非结核分枝杆菌肺病（NTM-PD）管理指南。
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
8
Outcomes of complex lung disease based on clinical phenotype.基于临床表型的复杂肺部疾病的结局。
Eur Respir J. 2017 Sep 27;50(3). doi: 10.1183/13993003.02503-2016. Print 2017 Sep.
9
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.鸟分枝杆菌胞内复合群肺病治疗中微生物学结局的Meta分析及证据基础
J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311.
10
Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.获得性大环内酯耐药脓肿分枝杆菌肺病患者的临床特征和治疗结局。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01146-17. Print 2017 Oct.
Zotero 插件